O besity occurs when whole-body energy intake exceeds energy expenditure for prolonged periods. This is a major public health issue because obesity increases the risk of disorders such as type 2 diabetes mellitus (T2DM). The liver and muscle store excess energy in the form of fat, leading to resistance to the hormone insulin. Released when blood glucose rises after meals, insulin normally promotes glucose uptake by muscle and represses glucose production by the liver, thus rapidly returning blood glucose to normal. However, this process is impaired in insulin-resistant individuals, who may eventually develop persistently elevated blood glucose (i.e., T2DM), which can cause debilitating or life-threatening complications. Because the energy sensor AMPK (adenosine monophosphate-activated protein kinase) promotes muscle glucose uptake by insulin-independent mechanisms, it was proposed in 1999 that AMPK-activating drugs might represent a novel approach to treating T2DM (1). Representing the culmination of more than 15 years of developing this concept, a study by Myers et al. (2) on page 507 of this issue and a study by Cokorinos et al. (3) show that compounds that bind to a unique site on AMPK can promote glucose uptake by muscle, and hence reverse elevated blood glucose in animal models of T2DM.
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AMPK senses cellular energy status by monitoring the levels of AMP, ADP, and ATP (adenosine mono-, di-, and triphosphates) (4) . ATP and ADP can be likened to the chemicals in a rechargeable battery, with a high ATP:ADP ratio being equivalent to a fully charged battery; AMP is a breakdown (12) . Importation of salamanders through the pet trade posed the greatest risk of pathogen introduction, and this threat led to lobbying for an importation ban by academics, government officials, and nongovernment organizations, supported by the private sector. Resulting legislation banned the import of 20 salamander genera; a voluntary moratorium by the Pet Industry Joint Advisory Council included additional genera. This example illustrates the power of multiple stakeholders to implement meaningful regulations and voluntary measures in a timely fashion in order to reduce the threat from chytrid fungi.
At the time of writing, salamander chytrid fungus has not been detected in the United States. However, this does not reduce the need for a more comprehensive and permanent legislative solution to wildlife health issues and a mature postinvasion plan should the fungus be detected. Both prevention and options for mitigation need to be part of a considered response to this threat. Furthermore, recent reports that the salamander chytrid fungus can infect hosts other than salamanders suggest that it may emerge even in areas without native salamander fauna, such as Australia and southern Africa (12) .
Many areas of the globe still remain naïve to emerging parasitic chytrid fungi (see the figure) . For example, disease surveys in New Guinea suggest that its frog fauna (which represents 6% of global frog species) may not yet have been exposed to amphibian chytrids, despite the fact that this remote island is climatically suitable for the parasitic fungi (13) . Although the data are sparse, they suggest that New Guinea may be one area where preemptive disease mitigation could save species such as Litoria auae (see the photo) from decline and possible extinction.
There is a distinct opportunity for rapid, preemptive action for policy, legislation, and management informed by a strategic investment to protect the biodiversity of remaining refuges from parasitic chytrid fungi. Although significant outcomes arose from preemptive responses to the threat of the salamander chytrid fungus in the United States, greater impact (such as from comprehensive and permanent legislative solutions) is still hindered by lack of disease policy, fragmented management responsibility, multiple competing objectives, and few effective options for postemergence control (14) . These problems are likely to be magnified in developing countries, where many species are undescribed and their ecology is unknown, providing an additional hurdle to effective conservation. Aid and scientific expertise from international sources must flow to regions that are a last remaining refuge for a large proportion of the world's amphibian species.
Comparatively cheap measures, such as lobbying for protective legislation to avoid introduction of wildlife diseases and strategically developing early response plans, will be more effective than post hoc attempts at species salvation. Estimates for effective conservation of 29 threatened frog species in Australia were costed at AU$15 million over 5 years (15) . Wildlife disease is often an additional threat to species already exposed to overexploitation, habitat loss, and climate change; approaches to conservation need to be approached strategically. Efficient management of remaining refugia requires immediate collaboration among scientists, policy-makers, managers, and local landowners together with commitment and funds. By acting now to identify remaining refugia, document fauna, improve biosecurity, and plan contingency responses, funds, and species can be saved long term. j sciencemag.org SCIENCE GRAPHIC: A. KITTERMAN/SCIENCE product of ADP. AMPK is activated by rising AMP:ATP and ADP:ATP ratios (which signify falling cellular energy levels) and acts to restore energy balance by switching on metabolic pathways that generate ATP (catabolism) while switching off processes that consume ATP, including anabolism.
The potential of AMPK activation for treatment of T2DM was reinforced by findings that it was activated by metformin (5) . Metformin is the frontline drug treatment in T2DM, prescribed to more than 150 million patients worldwide. It activates AMPK by inhibiting mitochondrial ATP synthesis, thus increasing cellular AMP and ADP concentrations. Given this indirect mechanism, it is not surprising that metformin has multiple effects, some (6) but not all (7) of which are AMPK-independent. Nonetheless, the effects of metformin are largely confined to the liver and gut, so drugs that activate AMPK in muscle might have additional benefits.
AMPK exists as complexes comprising three subunits-a catalytic a subunit and regulatory b and g subunits, with multiple isoforms (a1, a2, b1, b2, g1, g2, and g3)-giving rise to 12 possible complexes that have tissue-specific expression patterns (4) . Repeated sequences in the g subunits generate three binding sites for AMP, ADP, and ATP, and some AMPK activators target these. However, a new regulatory mechanism was discovered when a new activator, A-769662, was identified (8) . Although it mimicked two of the activating effects of AMP on AMPK, A-769662 clearly bound at a different site (9) , which was identified when an AMPK complex was crystallized in the presence of A-769662 or another activator, 991 (10). This site is unique to AMPK and is called the allosteric drug and metabolite (ADaM) site (11) . Although this site is currently only known to bind synthetic activators, it is widely assumed that there are unidentified cellular metabolite(s) that bind there [one natural product, salicylate, binds the site (12) but only occurs in plants].
The new ADaM site activators MK-8722, reported by Myers et al., and PF-739, reported by Cokorinos et al., are remarkably similar. Previous activators that bind the ADaM site, such as A-769662, are more specific for complexes containing the b1 isoform, but MK-8722 and PF-739 activate both b1 and b2 complexes. This is important because b1 is mainly expressed in the liver (at least in rodents), whereas muscle expresses mainly b2. MK-8722 is a potent activator of all 12 human AMPK complexes. Consistent with its ability to activate b2 complexes, MK-8722 enhanced glucose uptake by skeletal muscle in vitro and improved glucose tolerance in several rodent models of T2DM in vivo; in diabetic nonhuman primates (rhesus macaques), MK-8722 improved glucose tolerance and lowered hemoglobin A1c (HbA1c), a marker of persistently elevated blood glucose (2).
Cokorinos et al. (3) showed that, like MK-8722, PF-739 activated muscle AMPK and lowered blood glucose in mice with diet-induced obesity. PF-739 did not affect glucose production by the liver but increased peripheral glucose disposal in vivo. Consistent with this finding, the absence of a1 and a2 in the liver had no impact on blood glu cose reduction by PF-739, whereas their absence in muscle attenuated it. PF-739 also lowered blood glucose and insulin concentrations in nondiabetic cynomolgus monkeys. Therefore, blood glucose reduction requires a "pan-b" activator that acts on the b2 isoform expressed in muscle (see the figure) . However, b1-selective activators may still be useful. For example, a b1-selective activator, PF-06409577, activated AMPK in the kidney and reduced urinary protein content and other markers of kidney damage in a rat model of diabetic kidney disease (13) .
The results with MK-8722 and PF-739 are promising, because the new compounds exert effects on blood glucose via actions on muscle and would therefore be expected to have beneficial effects beyond that of metformin. However, concerns about adverse effects of AMPK activators were raised by previous studies of humans with mutations in the gene that encodes the g2 subunit. These mutations increase basal AMPK activity and are associated with increases in cardiac glycogen content and hypertrophy (increased heart weight) as well as potentially life-threatening cardiac arrhythmias (14) . Indeed, Myers et al. found that long-term use of MK-8722 in rats and rhesus macaques was associated with increased cardiac glycogen content and hypertrophy, although not with arrhythmias. Cardiac effects of PF-739 were not reported, so it remains unclear whether they are common to all pan-b activators.
Thus, MK-8722 and PF-739 were effective in reversing elevated blood glucose concentration in rodents and nonhuman primates, and this was due to activation of AMPK in muscle, not the liver. This might make them valuable adjuncts to metformin, which acts primarily on the liver. One caveat is their potential to cause cardiac hypertrophy, which is likely to raise concerns with regulatory authorities. However, as Myers et al. point out, the cardiac hypertrophy observed with MK-8722 treatment is reminiscent of that found in elite athletes (which may result from AMPK activation in cardiac muscle during training) and does not necessarily have adverse consequences. Currently, there are several AMPK activators that bind the ADaM site; whether there is a natural metabolite that binds there remains unclear, although those in the field may now be stimulated to look. j
